000195003 001__ 195003
000195003 005__ 20250127125059.0
000195003 037__ $$aDZNE-2023-00186
000195003 1001_ $$0P:(DE-2719)2810938$$aMüller, Stephan A$$b0
000195003 245__ $$aDataset: Cerebrospinal Fluid (CSF) Proteomics of A30P-αS mice
000195003 260__ $$bPRoteomics IDEntifications Database$$c2022
000195003 3367_ $$2BibTeX$$aMISC
000195003 3367_ $$0PUB:(DE-HGF)32$$2PUB:(DE-HGF)$$aDataset$$bdataset$$mdataset$$s1737978647_25504
000195003 3367_ $$026$$2EndNote$$aChart or Table
000195003 3367_ $$2DataCite$$aDataset
000195003 3367_ $$2ORCID$$aDATA_SET
000195003 3367_ $$2DINI$$aResearchData
000195003 520__ $$aHere, we took advantage of well-defined mouse models for α-synucleinopathy (A30P-αS ) to explore proteome changes in the cerebrospinal fluid which are related to these distinct proteopathic lesions. Non-targeted liquid chromatography-mass spectrometry revealed that the majority of proteins that undergo age- and disease-related changes in either mouse model was linked to microglia, and more specifically to previously described disease state-specific microglia transcriptomic signatures. The finding that such transcriptomic changes translate into corresponding protein changes in cerebrospinal fluid is of high clinical relevance, supporting efforts to identify bodily fluid biomarkers that reflect the various functional states of microglial activation in Parkinson’s disease.
000195003 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x0
000195003 7001_ $$0P:(DE-2719)2181459$$aLichtenthaler, Stefan$$b1
000195003 7870_ $$0DZNE-2022-01184$$aEninger, Timo et.al.$$dWashington, DC : National Acad. of Sciences, 2022$$iRelatedTo$$r$$tSignatures of glial activity can be detected in the CSF proteome
000195003 8564_ $$uhttps://www.ebi.ac.uk/pride/archive/projects/PXD021356
000195003 909CO $$ooai:pub.dzne.de:195003$$pVDB
000195003 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810938$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000195003 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2181459$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000195003 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x0
000195003 9141_ $$y2022
000195003 9201_ $$0I:(DE-2719)1110006$$kAG Lichtenthaler$$lNeuroproteomics$$x0
000195003 980__ $$adataset
000195003 980__ $$aVDB
000195003 980__ $$aI:(DE-2719)1110006
000195003 980__ $$aUNRESTRICTED